甘精胰岛素联合格列美脲治疗初诊2型糖尿病的疗效观察

Effect of insulin glargine combined with glimepiride in treating newly diagnosed type II diabetes mellitus

目的观察甘精胰岛素联合格列美脲治疗初诊2型糖尿病患者的临床疗效。方法 60例初诊2型糖尿病患者随机分为两组,对照组予诺和灵30R早晚餐前皮下注射,治疗组予早餐前口服格列美脲,睡前皮下注射甘精胰岛素,观察治疗12周后两组疗效、胰岛素日用量及安全性。结果两组空腹血糖、餐后两小时血糖、糖化血红蛋白均有明显下降,血糖达标时间相近,两组之间无明显差异,但胰岛素日用量、低血糖发生率治疗组低于对照组,有显著差异。结论甘精胰岛素联合格列美脲治疗初诊2型糖尿病能使患者血糖控制良好,胰岛素日用量少,且低血糖发生率低,病人依从性好。

Objective To observe the effect of insulin glargine combined with glimepiride in the treating type II diabetic patients. Methods 60 patients were randomly divided into two groups, control group to early subcutaneous injection Novolin 30R before dinner, the treatment group to oral glimepiride before breakfast, bedtime subcutaneous injection of insulin glargine, after 12 weeks observed the treat- ment effect of insulin daily dosage and safety. Results Two groups of fasting blood glucose, postprandi- al two hour blood glucose, glycosylated hemoglobin was obviously decreased, the glycemic goals similar to the time, between the two groups had no significant difference, but insulin daily volume, hypoglyce- mia incidence rate in the treatment group than the control group. Conclusions Insulin glargine and glimepiride treatment in type II diabetes can make patients with good glycemic control, insulin daily con- sumption, and low incidence of hypoglycemia, patient compliance is good.